243 related articles for article (PubMed ID: 31562117)
1. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study.
Kim NH; Han KH; Choi J; Lee J; Kim SG
BMJ; 2019 Sep; 366():l5125. PubMed ID: 31562117
[TBL] [Abstract][Full Text] [Related]
2. Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort study.
Kim NH; Choi J; Kim YH; Lee H; Kim SG
Diabetes Metab; 2023 May; 49(3):101428. PubMed ID: 36720383
[TBL] [Abstract][Full Text] [Related]
3. Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study.
Kim NH; Kim JY; Choi J; Kim SG
Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):118-127. PubMed ID: 38017618
[TBL] [Abstract][Full Text] [Related]
4. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
5. Effects of combination lipid therapy in type 2 diabetes mellitus.
; Ginsberg HN; Elam MB; Lovato LC; Crouse JR; Leiter LA; Linz P; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm RH; Ismail-Beigi F; Bigger JT; Goff DC; Cushman WC; Simons-Morton DG; Byington RP
N Engl J Med; 2010 Apr; 362(17):1563-74. PubMed ID: 20228404
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
7. Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older.
Orkaby AR; Driver JA; Ho YL; Lu B; Costa L; Honerlaw J; Galloway A; Vassy JL; Forman DE; Gaziano JM; Gagnon DR; Wilson PWF; Cho K; Djousse L
JAMA; 2020 Jul; 324(1):68-78. PubMed ID: 32633800
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT
Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360
[TBL] [Abstract][Full Text] [Related]
9. Statin and clinical outcomes of primary prevention in individuals aged >75 years: The SCOPE-75 study.
Kim K; Lee CJ; Shim CY; Kim JS; Kim BK; Park S; Chang HJ; Hong GR; Ko YG; Kang SM; Choi D; Ha JW; Hong MK; Jang Y; Lee SH
Atherosclerosis; 2019 May; 284():31-36. PubMed ID: 30870705
[TBL] [Abstract][Full Text] [Related]
10. Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry.
Alehagen U; Benson L; Edner M; Dahlström U; Lund LH
Circ Heart Fail; 2015 Mar; 8(2):252-60. PubMed ID: 25575580
[TBL] [Abstract][Full Text] [Related]
11. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.
Papademetriou V; Lovato L; Tsioufis C; Cushman W; Applegate WB; Mottle A; Punthakee Z; Nylen E; Doumas M;
Am J Nephrol; 2017; 45(2):136-145. PubMed ID: 27992863
[TBL] [Abstract][Full Text] [Related]
12. Statin therapy and risks for death and hospitalization in chronic heart failure.
Go AS; Lee WY; Yang J; Lo JC; Gurwitz JH
JAMA; 2006 Nov; 296(17):2105-11. PubMed ID: 17077375
[TBL] [Abstract][Full Text] [Related]
13. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
Keating GM; Croom KF
Drugs; 2007; 67(1):121-53. PubMed ID: 17209672
[TBL] [Abstract][Full Text] [Related]
15. Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.
Pursnani A; Massaro JM; D'Agostino RB; O'Donnell CJ; Hoffmann U
JAMA; 2015 Jul; 314(2):134-41. PubMed ID: 26172893
[TBL] [Abstract][Full Text] [Related]
16. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
[TBL] [Abstract][Full Text] [Related]
17. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
18. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.
Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T;
Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012
[TBL] [Abstract][Full Text] [Related]
19. [A meta-analysis on the safety of combination therapy with fenofibrate and statins].
Geng Q; Ren JY; Li SF; Chen H
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Dec; 41(12):1063-8. PubMed ID: 24524615
[TBL] [Abstract][Full Text] [Related]
20. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials.
Geng Q; Ren J; Chen H; Lee C; Liang W
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):219-26. PubMed ID: 23324122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
